EGFR and non-small cell lung carcinoma: In light of the consolidated notion that TP53 genomic alterations have a negative impact on therapeutic responses to EGFR tyrosine kinase inhibitors in advanced EGFR-mutated NSCLC [27,33], it will be interesting to assess whether TP53 mutations have an impact on responses to osimertinib also in early-stage NSCLC patients.